Newly Diagnosed? Receive Support from a Peer Volunteer

The Leukemia & Lymphoma Society (LLS) does some pretty neat things. As the world's largest voluntary health organization dedicated to funding blood cancer research, education, and patient services, LLS's mission is to cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families.



One of the programs they offer that’s pretty neat is The First Connection program. It provides newly diagnosed patients, caregivers and their families the opportunity to speak with someone who has "been through it" by talking with a trained Peer volunteer by phone.



Trained Peers can share their experience in a hopeful way and provide helpful information for anyone still in the treatment process.


Information about Society and community resources are also available.


Patient and volunteers are matched by age, diagnosis and gender when possible.


Any blood cancer patient or caregiver is eligible to receive a call.


There is no charge for this program. Find out more at http://www.leukemia-lymphoma.org/all_page?item_id=398848.

Blog Category: 

More Articles

More Articles

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

In a large trial of older, newly diagnosed patients with chronic lymphocytic leukemia (CLL),...

Today’s typical treatments have been unable to cure numerous types of lymphoma, but emerging immunotherapies could provide the key to...

Biotech firm Gilead Sciences Inc. has announced that the first patient has been dosed in a Phase III trial evaluating the safety and efficacy of...

Last week at the 54th American Society of Hematology Annual Meeting and Exposition in Atlanta, researchers out of MD Anderson Cancer Center in...

The results of a pair of long-term survival studies indicate the therapeutic value of BEXXAR (...

A new lab test that can improve survival rates among patients with chronic lymphocytic leukemia (...

Aggressive Non-Hodgkin’s Lymphomas (NHLs) are fast growing cancers (as opposed to indolent cancers). They involve...

A B cell is a type of lymphocyte that produces antibodies to fight infections. These are the most prevalent lymphocytes in the bloodstream and are...

Sitemap